Acute Market Reports – article directory

Polycystic Ovarian Syndrome (PCOS) Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 the global polycystic ovarian syndrome (PCOS) therapeutics market was valued at US$ 784.74 Mn in 2016, and is expected to reach US$ 1,162.1 Mn by 2025, expanding at a CAGR of 4.47% from 2017 to 2025.

Browse Full Report here


Market Insights
Polycystic ovarian syndrome (PCOS) therapeutics market is expected to show significant market growth during the forecast period due to growing prevalence of PCOS, rising treatment awareness and significant unmet needs. For the purpose of study, global PCOS therapeutics market is segmented on the basis of drug type such as oral contraceptive, ovulation inducing agents, facial hair growth inhibitor, insulin sensitizing agent and others. In the base year 2016, oral contraceptive was major revenue contributing segment due to its effectiveness to regulate PCOS symptoms such as reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the acne and to regulate the menstrual periods. PCOS therapeutics market is currently dominated by North America, factors such as higher cost of therapeutics, higher number of targeted population, government reimbursement policies in healthcare infrastructure and early diagnosis are fueling the growth of PCOS therapeutics market in North America. However, Asia-Pacific is anticipated to show highest market growth during forecast period due to rising number of target population, improving healthcare infrastructure and increasing treatment awareness.

Market Competition Assessment:
The polycystic ovarian syndrome (PCOS) therapeutics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Teva Pharmaceutical Industries Limited, Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc., Sanofi Aventis and other.

Key Market Movements:
• Factors such as rising prevalence PCOS and increasing popularity of combination drugs are driving the market growth of PCOS therapeutics market worldwide.
• Due to the high unmet needs, vendors in the market are focusing in development of ideal treatment, rising access for the treatment medication in some developing countries would fuel the growth of PCOS therapeutics market during forecast period.
• Currently, there is large PCOS therapeutic market potential for new entrants due to lack of approved and efficient drug in market also absence of a strong pipeline molecules.
• Lack of regulatory approved therapeutics and adverse effects associated with off-label products are negatively impacting the growth of PCOS therapeutics market globally.

Browse the complete report at


Table of Content:

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Snapshot
2.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type
2.3 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Analysis
3.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
3.5 Top 3 Countries


Download Free Request Sample


Chapter 6 Company Profiles
6.1 Bristol Myers Squibb
6.2 Crinetics Pharmaceuticals, Inc.
6.3 EffRx, Inc.
6.4 Ferring Pharmaceuticals
6.5 Merck KGaA
6.6 Neurocrine Biosciences, Inc.
6.7 Novartis Pharmaceuticals
6.8 Pfizer Inc.
6.9 Sanofi Aventis
6.10 Teva Pharmaceutical Industries Limited


Latest Reports:


About – Acute Market Reports:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.


Contact Us:

Name: Chris Paul


Designation: Global Sales Manager

Toll Free (US/CANADA): +1-855-455-8662





The Article Source

Leave a Reply

Your email address will not be published. Required fields are marked *